FDA Expands Indication for Amivantamab in Lung Cancer
Amivantamab plus chemo is now indicated in locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations after disease progression on or after an EGFR-TKI.
Medscape Medical News
source https://www.medscape.com/viewarticle/fda-expands-indication-amivantamab-lung-cancer-2024a1000h79?src=rss
Medscape Medical News
source https://www.medscape.com/viewarticle/fda-expands-indication-amivantamab-lung-cancer-2024a1000h79?src=rss
Comments
Post a Comment